Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 17 entries
Sorted by: Best Match Show Resources per page
Adsorption of Bacteriophage eb7 on Streptococcus cremoris EB7.

Applied and environmental microbiology

Keogh BP, Pettingill G.
PMID: 16346324
Appl Environ Microbiol. 1983 Jun;45(6):1946-8. doi: 10.1128/aem.45.6.1946-1948.1983.

When M17 broth was used as growth medium before preparation of cell walls, adsorption of phage eb7 on Streptococcus cremoris EB7 at pH 4.0 was stimulated. When preparation included treatment with trypsin, absorption of phage was 65%. Without trypsin...

Cite
Keogh BP, Pettingill G. Adsorption of Bacteriophage eb7 on Streptococcus cremoris EB7. Appl Environ Microbiol. 1983;45(6):1946-8doi: 10.1128/aem.45.6.1946-1948.1983.
Keogh, B. P., & Pettingill, G. (1983). Adsorption of Bacteriophage eb7 on Streptococcus cremoris EB7. Applied and environmental microbiology, 45(6), 1946-8. https://doi.org/10.1128/aem.45.6.1946-1948.1983
Keogh, B P, and Pettingill, G. "Adsorption of Bacteriophage eb7 on Streptococcus cremoris EB7." Applied and environmental microbiology vol. 45,6 (1983): 1946-8. doi: https://doi.org/10.1128/aem.45.6.1946-1948.1983
Keogh BP, Pettingill G. Adsorption of Bacteriophage eb7 on Streptococcus cremoris EB7. Appl Environ Microbiol. 1983 Jun;45(6):1946-8. doi: 10.1128/aem.45.6.1946-1948.1983. PMID: 16346324; PMCID: PMC242565.
Copy Download .nbib Format: NLM
Inhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cells.

Oncotarget

Alharbi RA, Pandha HS, Simpson GR, Pettengell R, Poterlowicz K, Thompson A, Harrington K, El-Tanani M, Morgan R.
PMID: 29163771
Oncotarget. 2017 Aug 07;8(52):89566-89579. doi: 10.18632/oncotarget.20023. eCollection 2017 Oct 27.

The HOX genes encode a family of transcription factors that have key roles in both development and malignancy. Disrupting the interaction between HOX proteins and their binding partner, PBX, has been shown to cause apoptotic cell death in a...

Cite
Alharbi RA, Pandha HS, Simpson GR, et al. Inhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cells. Oncotarget. 2017;8(52):89566-89579doi: 10.18632/oncotarget.20023.
Alharbi, R. A., Pandha, H. S., Simpson, G. R., Pettengell, R., Poterlowicz, K., Thompson, A., Harrington, K., El-Tanani, M., & Morgan, R. (2017). Inhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cells. Oncotarget, 8(52), 89566-89579. https://doi.org/10.18632/oncotarget.20023
Alharbi, Raed A, et al. "Inhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cells." Oncotarget vol. 8,52 (2017): 89566-89579. doi: https://doi.org/10.18632/oncotarget.20023
Alharbi RA, Pandha HS, Simpson GR, Pettengell R, Poterlowicz K, Thompson A, Harrington K, El-Tanani M, Morgan R. Inhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cells. Oncotarget. 2017 Aug 07;8(52):89566-89579. doi: 10.18632/oncotarget.20023. eCollection 2017 Oct 27. PMID: 29163771; PMCID: PMC5685692.
Copy Download .nbib Format: NLM
Pathogenic potential of antibodies to the GABA.

Epilepsia open

Nibber A, Mann EO, Pettingill P, Waters P, Irani SR, Kullmann DM, Vincent A, Lang B.
PMID: 29588966
Epilepsia Open. 2017 Jul 19;2(3):355-359. doi: 10.1002/epi4.12067. eCollection 2017 Sep.

GABA

Cite
Nibber A, Mann EO, Pettingill P, et al. Pathogenic potential of antibodies to the GABA. Epilepsia Open. 2017;2(3):355-359doi: 10.1002/epi4.12067.
Nibber, A., Mann, E. O., Pettingill, P., Waters, P., Irani, S. R., Kullmann, D. M., Vincent, A., & Lang, B. (2017). Pathogenic potential of antibodies to the GABA. Epilepsia open, 2(3), 355-359. https://doi.org/10.1002/epi4.12067
Nibber, Anjan, et al. "Pathogenic potential of antibodies to the GABA." Epilepsia open vol. 2,3 (2017): 355-359. doi: https://doi.org/10.1002/epi4.12067
Nibber A, Mann EO, Pettingill P, Waters P, Irani SR, Kullmann DM, Vincent A, Lang B. Pathogenic potential of antibodies to the GABA. Epilepsia Open. 2017 Jul 19;2(3):355-359. doi: 10.1002/epi4.12067. eCollection 2017 Sep. PMID: 29588966; PMCID: PMC5862107.
Copy Download .nbib Format: NLM
Growth factors in haematological cancers.

Expert opinion on emerging drugs

Osuji N, Pettengell R.
PMID: 15989543
Expert Opin Emerg Drugs. 2002 May;7(1):175-88. doi: 10.1517/14728214.7.1.175.

Since their discovery just under a century ago, growth factors (GFs) have been used almost ubiquitously in haematology. Many haematological cancers are associated with bone marrow failure, either as a direct consequence of the disease or its treatment. Colony...

Cite
Osuji N, Pettengell R. Growth factors in haematological cancers. Expert Opin Emerg Drugs. 2002;7(1):175-88doi: 10.1517/14728214.7.1.175.
Osuji, N., & Pettengell, R. (2002). Growth factors in haematological cancers. Expert opinion on emerging drugs, 7(1), 175-88. https://doi.org/10.1517/14728214.7.1.175
Osuji, Nnenna, and Pettengell, R. "Growth factors in haematological cancers." Expert opinion on emerging drugs vol. 7,1 (2002): 175-88. doi: https://doi.org/10.1517/14728214.7.1.175
Osuji N, Pettengell R. Growth factors in haematological cancers. Expert Opin Emerg Drugs. 2002 May;7(1):175-88. doi: 10.1517/14728214.7.1.175. PMID: 15989543.
Copy Download .nbib Format: NLM
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.

Blood advances

Davids MS, O'Connor OA, Jurczak W, Samaniego F, Fenske TS, Zinzani PL, Patel MR, Ghosh N, Cheson BD, Derenzini E, Brander DM, Reeves JA, Knopińska-Posłuszny W, Allan JN, Phillips T, Caimi PF, Lech-Maranda E, Burke JM, Agajanian R, Pettengell R, Leslie LA, Cheah CY, Fonseca G, Essell J, Chavez JC, Pagel JM, Sharman JP, Hsu Y, Miskin HP, Sportelli P, Weiss MS, Flinn IW.
PMID: 34547767
Blood Adv. 2021 Dec 14;5(23):5332-5343. doi: 10.1182/bloodadvances.2021005132.

Phosphoinositide 3-kinase-δ (PI3Kδ) inhibitors are active in lymphoid malignancies, although associated toxicities can limit their use. Umbralisib is a dual inhibitor of PI3Kδ and casein kinase-1ε (CK1ε). This study analyzed integrated comprehensive toxicity data from 4 open-label, phase 1...

Cite
Davids MS, O'Connor OA, Jurczak W, et al. Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies. Blood Adv. 2021;5(23):5332-5343doi: 10.1182/bloodadvances.2021005132.
Davids, M. S., O'Connor, O. A., Jurczak, W., Samaniego, F., Fenske, T. S., Zinzani, P. L., Patel, M. R., Ghosh, N., Cheson, B. D., Derenzini, E., Brander, D. M., Reeves, J. A., Knopińska-Posłuszny, W., Allan, J. N., Phillips, T., Caimi, P. F., Lech-Maranda, E., Burke, J. M., Agajanian, R., Pettengell, R., Leslie, L. A., Cheah, C. Y., Fonseca, G., Essell, J., Chavez, J. C., Pagel, J. M., Sharman, J. P., Hsu, Y., Miskin, H. P., Sportelli, P., Weiss, M. S., & Flinn, I. W. (2021). Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies. Blood advances, 5(23), 5332-5343. https://doi.org/10.1182/bloodadvances.2021005132
Davids, Matthew S, et al. "Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies." Blood advances vol. 5,23 (2021): 5332-5343. doi: https://doi.org/10.1182/bloodadvances.2021005132
Davids MS, O'Connor OA, Jurczak W, Samaniego F, Fenske TS, Zinzani PL, Patel MR, Ghosh N, Cheson BD, Derenzini E, Brander DM, Reeves JA, Knopińska-Posłuszny W, Allan JN, Phillips T, Caimi PF, Lech-Maranda E, Burke JM, Agajanian R, Pettengell R, Leslie LA, Cheah CY, Fonseca G, Essell J, Chavez JC, Pagel JM, Sharman JP, Hsu Y, Miskin HP, Sportelli P, Weiss MS, Flinn IW. Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies. Blood Adv. 2021 Dec 14;5(23):5332-5343. doi: 10.1182/bloodadvances.2021005132. PMID: 34547767.
Copy Download .nbib Format: NLM
More access isn't enough. Reform must include health promotion, oversight board, simplification.

Modern healthcare

Pettingill R.
PMID: 19415831
Mod Healthc. 2009 Mar 16;39(11):18.

No abstract available.

Cite
Pettingill R. More access isn't enough. Reform must include health promotion, oversight board, simplification. Mod Healthc. 2009;39(11):18
Pettingill, R. (2009). More access isn't enough. Reform must include health promotion, oversight board, simplification. Modern healthcare, 39(11), 18.
Pettingill, Richard. "More access isn't enough. Reform must include health promotion, oversight board, simplification." Modern healthcare vol. 39,11 (2009): 18.
Pettingill R. More access isn't enough. Reform must include health promotion, oversight board, simplification. Mod Healthc. 2009 Mar 16;39(11):18. PMID: 19415831.
Copy Download .nbib Format: NLM
Development of a heterogeneous phantom to measure range in clinical proton therapy beams.

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)

Cook H, Lambert J, Thomas R, Palmans H, Hussein M, Clark CH, Royle G, Pettingell J, Lourenço A.
PMID: 34968893
Phys Med. 2021 Dec 27;93:59-68. doi: 10.1016/j.ejmp.2021.11.006. Epub 2021 Dec 27.

PURPOSE: In particle therapy, determination of range by measurement or calculation can be a significant source of uncertainty. This work investigates the development of a bespoke Range Length Phantom (RaLPh) to allow independent determination of proton range in tissue....

Cite
Cook H, Lambert J, Thomas R, et al. Development of a heterogeneous phantom to measure range in clinical proton therapy beams. Phys Med. 2021;93:59-68doi: 10.1016/j.ejmp.2021.11.006.
Cook, H., Lambert, J., Thomas, R., Palmans, H., Hussein, M., Clark, C. H., Royle, G., Pettingell, J., & Lourenço, A. (2021). Development of a heterogeneous phantom to measure range in clinical proton therapy beams. Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB), 9359-68. https://doi.org/10.1016/j.ejmp.2021.11.006
Cook, H, et al. "Development of a heterogeneous phantom to measure range in clinical proton therapy beams." Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB) vol. 93 (2021): 59-68. doi: https://doi.org/10.1016/j.ejmp.2021.11.006
Cook H, Lambert J, Thomas R, Palmans H, Hussein M, Clark CH, Royle G, Pettingell J, Lourenço A. Development of a heterogeneous phantom to measure range in clinical proton therapy beams. Phys Med. 2021 Dec 27;93:59-68. doi: 10.1016/j.ejmp.2021.11.006. Epub 2021 Dec 27. PMID: 34968893.
Copy Download .nbib Format: NLM
Myeloid growth factors in oncology.

Expert opinion on investigational drugs

Lofts FJ, Pettengell R.
PMID: 15991939
Expert Opin Investig Drugs. 1998 Dec;7(12):1955-76. doi: 10.1517/13543784.7.12.1955.

Within the last decade haemopoietic growth factors have become established in the pharmacopoeia of oncology. In the form of granulocyte colony-stimulating factor (G-CSF), and to a lesser extent granulocyte-macrophage colony-stimulating factor (GM-CSF), these proteins are routinely used to accelerate...

Cite
Lofts FJ, Pettengell R. Myeloid growth factors in oncology. Expert Opin Investig Drugs. 1998;7(12):1955-76doi: 10.1517/13543784.7.12.1955.
Lofts, F. J., & Pettengell, R. (1998). Myeloid growth factors in oncology. Expert opinion on investigational drugs, 7(12), 1955-76. https://doi.org/10.1517/13543784.7.12.1955
Lofts, F J, and Pettengell, R. "Myeloid growth factors in oncology." Expert opinion on investigational drugs vol. 7,12 (1998): 1955-76. doi: https://doi.org/10.1517/13543784.7.12.1955
Lofts FJ, Pettengell R. Myeloid growth factors in oncology. Expert Opin Investig Drugs. 1998 Dec;7(12):1955-76. doi: 10.1517/13543784.7.12.1955. PMID: 15991939.
Copy Download .nbib Format: NLM
Possible role of coryneform bacteria in age gelation of ultrahigh-temperature-processed milk.

Applied and environmental microbiology

Keogh BP, Pettingill G.
PMID: 16346043
Appl Environ Microbiol. 1982 Jun;43(6):1495-7. doi: 10.1128/aem.43.6.1495-1497.1982.

Two strains of psychrotrophic, gram-positive, proteolytic bacteria isolated from raw milk were identified as Arthrobacter or closely related coryneform species. We inoculated raw-milk samples with the strains (one strain per sample) and compared rates of gelation after ultrahigh-temperature processing...

Cite
Keogh BP, Pettingill G. Possible role of coryneform bacteria in age gelation of ultrahigh-temperature-processed milk. Appl Environ Microbiol. 1982;43(6):1495-7doi: 10.1128/aem.43.6.1495-1497.1982.
Keogh, B. P., & Pettingill, G. (1982). Possible role of coryneform bacteria in age gelation of ultrahigh-temperature-processed milk. Applied and environmental microbiology, 43(6), 1495-7. https://doi.org/10.1128/aem.43.6.1495-1497.1982
Keogh, B P, and Pettingill, G. "Possible role of coryneform bacteria in age gelation of ultrahigh-temperature-processed milk." Applied and environmental microbiology vol. 43,6 (1982): 1495-7. doi: https://doi.org/10.1128/aem.43.6.1495-1497.1982
Keogh BP, Pettingill G. Possible role of coryneform bacteria in age gelation of ultrahigh-temperature-processed milk. Appl Environ Microbiol. 1982 Jun;43(6):1495-7. doi: 10.1128/aem.43.6.1495-1497.1982. PMID: 16346043; PMCID: PMC244258.
Copy Download .nbib Format: NLM
Relaxation and exercise in lymphoma survivors (REIL study): a randomised clinical trial protocol.

BMC sports science, medicine & rehabilitation

Hathiramani S, Pettengell R, Moir H, Younis A.
PMID: 31428434
BMC Sports Sci Med Rehabil. 2019 Aug 16;11:17. doi: 10.1186/s13102-019-0127-7. eCollection 2019.

BACKGROUND: Lymphoma survivors commonly report ongoing complaints including fatigue, pain, depression and decreased quality of life (QoL) following treatment. Although evidence suggests that both relaxation and exercise can significantly improve such symptoms, there is no consensus on which intervention...

Cite
Hathiramani S, Pettengell R, Moir H, et al. Relaxation and exercise in lymphoma survivors (REIL study): a randomised clinical trial protocol. BMC Sports Sci Med Rehabil. 2019;11:17doi: 10.1186/s13102-019-0127-7.
Hathiramani, S., Pettengell, R., Moir, H., & Younis, A. (2019). Relaxation and exercise in lymphoma survivors (REIL study): a randomised clinical trial protocol. BMC sports science, medicine & rehabilitation, 1117. https://doi.org/10.1186/s13102-019-0127-7
Hathiramani, Suchita, et al. "Relaxation and exercise in lymphoma survivors (REIL study): a randomised clinical trial protocol." BMC sports science, medicine & rehabilitation vol. 11 (2019): 17. doi: https://doi.org/10.1186/s13102-019-0127-7
Hathiramani S, Pettengell R, Moir H, Younis A. Relaxation and exercise in lymphoma survivors (REIL study): a randomised clinical trial protocol. BMC Sports Sci Med Rehabil. 2019 Aug 16;11:17. doi: 10.1186/s13102-019-0127-7. eCollection 2019. PMID: 31428434; PMCID: PMC6697965.
Copy Download .nbib Format: NLM
Influence of Enzyme Activity of Bacteria and Leucocytes in Raw Milk on Age Gelation after UHT Processing.

Journal of food protection

Keogh BP, Pettingill G.
PMID: 30921920
J Food Prot. 1984 Feb;47(2):105-107. doi: 10.4315/0362-028X-47.2.105.

An investigation was undertaken into the relationship between the enzyme activity of cells harvested from raw milk and time taken for age gelation (TAG) to occur in the milk after ultra-high-temperature processing. It was shown that there was no...

Cite
Keogh BP, Pettingill G. Influence of Enzyme Activity of Bacteria and Leucocytes in Raw Milk on Age Gelation after UHT Processing. J Food Prot. 1984;47(2):105-107doi: 10.4315/0362-028X-47.2.105.
Keogh, B. P., & Pettingill, G. (1984). Influence of Enzyme Activity of Bacteria and Leucocytes in Raw Milk on Age Gelation after UHT Processing. Journal of food protection, 47(2), 105-107. https://doi.org/10.4315/0362-028X-47.2.105
Keogh, Barbara P, and Pettingill, G. "Influence of Enzyme Activity of Bacteria and Leucocytes in Raw Milk on Age Gelation after UHT Processing." Journal of food protection vol. 47,2 (1984): 105-107. doi: https://doi.org/10.4315/0362-028X-47.2.105
Keogh BP, Pettingill G. Influence of Enzyme Activity of Bacteria and Leucocytes in Raw Milk on Age Gelation after UHT Processing. J Food Prot. 1984 Feb;47(2):105-107. doi: 10.4315/0362-028X-47.2.105. PMID: 30921920.
Copy Download .nbib Format: NLM
Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline.

British journal of haematology

Fox CP, Ahearne MJ, Pettengell R, Dearden C, El-Sharkawi D, Kassam S, Cook L, Cwynarski K, Illidge T, Collins G.
PMID: 34811725
Br J Haematol. 2021 Nov 22; doi: 10.1111/bjh.17951. Epub 2021 Nov 22.

No abstract available.

Cite
Fox CP, Ahearne MJ, Pettengell R, et al. Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline. Br J Haematol. 2021;doi: 10.1111/bjh.17951.
Fox, C. P., Ahearne, M. J., Pettengell, R., Dearden, C., El-Sharkawi, D., Kassam, S., Cook, L., Cwynarski, K., Illidge, T., & Collins, G. (2021). Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline. British journal of haematology, . https://doi.org/10.1111/bjh.17951
Fox, Christopher P, et al. "Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline." British journal of haematology vol. (2021). doi: https://doi.org/10.1111/bjh.17951
Fox CP, Ahearne MJ, Pettengell R, Dearden C, El-Sharkawi D, Kassam S, Cook L, Cwynarski K, Illidge T, Collins G. Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline. Br J Haematol. 2021 Nov 22; doi: 10.1111/bjh.17951. Epub 2021 Nov 22. PMID: 34811725.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 17 entries